CLPT Quote, Financials, Valuation and Earnings

Integra LifeSciences Holdings Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of -1.34%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 106.26%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 14.9%. Given that Clearpoint Neuro, Inc. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Integra LifeSciences Holdings Corp..

Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.408%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.47x versus 0.63x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Masimo Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 14.46%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Masimo Corp.'s return on equity of -19.18%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 106.26%. On the other hand Masimo Corp. has an analysts' consensus of $183.13 which suggests that it could grow by 32.61%. Given that Clearpoint Neuro, Inc. has higher upside potential than Masimo Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Masimo Corp..

Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Masimo Corp. has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.208%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Masimo Corp. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Masimo Corp. quarterly revenues of $371.5M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Masimo Corp.'s net income of $53.7M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Masimo Corp.'s PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.47x versus 4.36x for Masimo Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 7.29%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 106.26%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 3.89%. Given that Clearpoint Neuro, Inc. has higher upside potential than Phibro Animal Health Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Phibro Animal Health Corp..

Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phibro Animal Health Corp. offers a yield of 1.16% to investors and pays a quarterly dividend of $0.12 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Phibro Animal Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Phibro Animal Health Corp.'s PE ratio is 24.88x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.47x versus 1.21x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -66.48% compared to Clearpoint Neuro, Inc.'s net margin of 3.93%. Clearpoint Neuro, Inc.'s return on equity of -105.19% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Clearpoint Neuro, Inc. has a consensus price target of $29.00, signalling upside risk potential of 106.26%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 150.92%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Clearpoint Neuro, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Clearpoint Neuro, Inc..

Clearpoint Neuro, Inc. has a beta of 1.008, which suggesting that the stock is 0.79800000000001% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Clearpoint Neuro, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Clearpoint Neuro, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Clearpoint Neuro, Inc. quarterly revenues are $8.9M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Clearpoint Neuro, Inc.'s net income of -$5.9M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Clearpoint Neuro, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 58.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Clearpoint Neuro, Inc. is 11.47x versus 0.65x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.